Venus Medtech Clarifies Position on U.S. Patent Lawsuit and Market Disclosure Obligations
I'm PortAI, I can summarize articles.
Venus Medtech (Hangzhou), Inc. has clarified its position regarding a U.S. patent infringement lawsuit filed by its subsidiary Cardiovalve and joint venture MTH IP against Edwards Lifesciences. The company stated it is not aware of any information that requires disclosure under Hong Kong regulations to prevent a false market. Shareholders and potential investors are advised to exercise caution. The current analyst rating for Venus Medtech's stock (HK:2500) is Hold, with a price target of HK$3.50 and a market cap of HK$1.49B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments